OA11653A - Pharmaceutical agents for the treatment of parkisnon's disease, ADHD and microadenomas. - Google Patents

Pharmaceutical agents for the treatment of parkisnon's disease, ADHD and microadenomas. Download PDF

Info

Publication number: OA11653A
Authority: OA; OAPI
Prior art keywords: pharmaceutically acceptable; adhd; sait; receptor; adrenergic receptor
Prior art date: 1998-09-21

Application number

OA1200100068A

Other languages

English (en)

Inventor

Elisa Rse Jackson

Stafford Mclean

Stevin Howard Zorn

Original Assignee

Spfizer Products Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-21

Filing date

1999-09-03

Publication date

2004-12-08

1999-09-03 Application filed by Spfizer Products Inc filed Critical Spfizer Products Inc

2004-12-08 Publication of OA11653A publication Critical patent/OA11653A/en

Links

208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title claims abstract description 40
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title claims abstract description 40
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 17
201000010099 disease Diseases 0.000 title claims description 6
239000008177 pharmaceutical agent Substances 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 48
241000124008 Mammalia Species 0.000 claims abstract description 18
239000000203 mixture Substances 0.000 claims abstract description 18
208000018737 Parkinson disease Diseases 0.000 claims abstract description 11
239000003795 chemical substances by application Substances 0.000 claims description 45
101150049660 DRD2 gene Proteins 0.000 claims description 23
239000013543 active substance Substances 0.000 claims description 19
239000003446 ligand Substances 0.000 claims description 19
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims description 18
108060003345 Adrenergic Receptor Proteins 0.000 claims description 18
102000017910 Adrenergic receptor Human genes 0.000 claims description 18
239000002253 acid Substances 0.000 claims description 17
239000008194 pharmaceutical composition Substances 0.000 claims description 17
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims description 16
150000003839 salts Chemical class 0.000 claims description 15
239000000048 adrenergic agonist Substances 0.000 claims description 7
229940126157 adrenergic receptor agonist Drugs 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 7
239000000674 adrenergic antagonist Substances 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
230000003518 presynaptic effect Effects 0.000 claims description 6
230000001242 postsynaptic effect Effects 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
101100073357 Streptomyces halstedii sch2 gene Proteins 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims 4
PJEAHOHAPYWSEB-UHFFFAOYSA-N 4h-pyrido[1,2-a]pyrazine Chemical class C1=CC=CN2CC=NC=C21 PJEAHOHAPYWSEB-UHFFFAOYSA-N 0.000 abstract 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
238000000034 method Methods 0.000 description 24
239000000018 receptor agonist Substances 0.000 description 19
229940044601 receptor agonist Drugs 0.000 description 19
239000003814 drug Substances 0.000 description 14
230000000694 effects Effects 0.000 description 14
239000000556 agonist Substances 0.000 description 11
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 10
229940079593 drug Drugs 0.000 description 10
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
210000004027 cell Anatomy 0.000 description 8
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
239000000243 solution Substances 0.000 description 8
-1 4,4-dimethylpiperidine-2,6-dion-1-yl Chemical group 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
239000002609 medium Substances 0.000 description 6
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 5
239000000523 sample Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
239000002585 base Substances 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
238000011534 incubation Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
238000001690 micro-dialysis Methods 0.000 description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
FTSUPYGMFAPCFZ-ZWNOBZJWSA-N quinpirole Chemical compound C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 FTSUPYGMFAPCFZ-ZWNOBZJWSA-N 0.000 description 4
229950001037 quinpirole Drugs 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
102000017911 HTR1A Human genes 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
241000700159 Rattus Species 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
230000027455 binding Effects 0.000 description 3
QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 3
229960002495 buspirone Drugs 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000000502 dialysis Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
108010024941 iodothyronine deiodinase type II Proteins 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
229960002748 norepinephrine Drugs 0.000 description 3
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
229940076279 serotonin Drugs 0.000 description 3
239000007787 solid Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
ASXGJMSKWNBENU-CQSZACIVSA-N (7R)-7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1=CC(O)=C2C[C@H](N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-CQSZACIVSA-N 0.000 description 2
TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
208000019901 Anxiety disease Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
229910002651 NO3 Inorganic materials 0.000 description 2
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000004696 Poly ether ether ketone Substances 0.000 description 2
241000288906 Primates Species 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000008484 agonism Effects 0.000 description 2
GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000835 fiber Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000010304 firing Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 2
229960000647 gepirone Drugs 0.000 description 2
229940050410 gluconate Drugs 0.000 description 2
210000001320 hippocampus Anatomy 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
229950003599 ipsapirone Drugs 0.000 description 2
238000005567 liquid scintillation counting Methods 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
229920002530 polyetherether ketone Polymers 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000011084 recovery Methods 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
238000013222 sprague-dawley male rat Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
ZZJYIKPMDIWRSN-TZBSWOFLSA-N (+)-butaclamol Chemical compound C12=CC=CC=C2CCC2=CC=CC3=C2[C@@H]1CN1CC[C@@](C(C)(C)C)(O)C[C@@H]13 ZZJYIKPMDIWRSN-TZBSWOFLSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282461 Canis lupus Species 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
102000004420 Creatine Kinase Human genes 0.000 description 1
108010042126 Creatine kinase Proteins 0.000 description 1
229920001651 Cyanoacrylate Polymers 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
208000014094 Dystonic disease Diseases 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
239000007755 F10 Nutrient Mixture Substances 0.000 description 1
229940124602 FDA-approved drug Drugs 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101150015707 HTR1A gene Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229920005439 Perspex® Polymers 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
235000003434 Sesamum indicum Nutrition 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000036982 action potential Effects 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000000648 anti-parkinson Effects 0.000 description 1
239000000939 antiparkinson agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000001593 cAMP accumulation Effects 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
238000011161 development Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000000975 dye Substances 0.000 description 1
208000010118 dystonia Diseases 0.000 description 1
230000007831 electrophysiology Effects 0.000 description 1
238000002001 electrophysiology Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000003822 epoxy resin Substances 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000005350 fused silica glass Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000011521 glass Substances 0.000 description 1
229910021397 glassy carbon Inorganic materials 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
238000011597 hartley guinea pig Methods 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 description 1
229950001476 idazoxan Drugs 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229960001344 methylphenidate Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
238000000491 multivariate analysis Methods 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
229960004851 pergolide Drugs 0.000 description 1
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229950007002 phosphocreatine Drugs 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920000647 polyepoxide Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960003089 pramipexole Drugs 0.000 description 1
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
210000002442 prefrontal cortex Anatomy 0.000 description 1
230000002360 prefrontal effect Effects 0.000 description 1
239000002287 radioligand Substances 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
230000004044 response Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000009738 saturating Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000004515 ventral tegmental area Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
229960000317 yohimbine Drugs 0.000 description 1
AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA1200100068A 1998-09-21 1999-09-03 Pharmaceutical agents for the treatment of parkisnon's disease, ADHD and microadenomas. OA11653A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10119198P	1998-09-21	1998-09-21
US10386898P	1998-10-12	1998-10-12

Publications (1)

Publication Number	Publication Date
OA11653A true OA11653A (en)	2004-12-08

Family

ID=26798000

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100068A OA11653A (en)	1998-09-21	1999-09-03	Pharmaceutical agents for the treatment of parkisnon's disease, ADHD and microadenomas.

Country Status (38)

Country	Link
US (2)	US6300329B1 (id)
EP (1)	EP1115402A1 (id)
JP (1)	JP2002526448A (id)
KR (3)	KR20030088512A (id)
CN (1)	CN1319013A (id)
AP (1)	AP1456A (id)
AR (1)	AR029739A1 (id)
AU (1)	AU760230B2 (id)
BG (1)	BG105445A (id)
BR (1)	BR9913975A (id)
CA (1)	CA2344670A1 (id)
CO (1)	CO5140075A1 (id)
CZ (1)	CZ20011006A3 (id)
DZ (1)	DZ2894A1 (id)
EA (2)	EA200100204A1 (id)
EE (1)	EE200100179A (id)
GE (1)	GEP20033081B (id)
GT (1)	GT199900154A (id)
HN (1)	HN1999000146A (id)
HR (1)	HRP20010209A2 (id)
HU (1)	HUP0103691A3 (id)
ID (1)	ID28028A (id)
IL (2)	IL164839A0 (id)
IS (1)	IS5852A (id)
MA (1)	MA26690A1 (id)
MY (1)	MY127939A (id)
NO (1)	NO20011409L (id)
NZ (1)	NZ509855A (id)
OA (1)	OA11653A (id)
PA (1)	PA8482001A1 (id)
PE (1)	PE20001084A1 (id)
PL (1)	PL346904A1 (id)
SK (1)	SK3592001A3 (id)
TN (1)	TNSN99177A1 (id)
TR (2)	TR200402083T2 (id)
TW (1)	TW518225B (id)
WO (1)	WO2000016777A1 (id)
YU (1)	YU21701A (id)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HN1999000146A (es) *	1998-09-21	2000-11-11	Pfizer Prod Inc	Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
WO2001068104A1 (en) *	2000-03-16	2001-09-20	The Mclean Hospital Corporation	Compounds for the treatment of psychiatric or substance abuse disorders
GB0027020D0 (en) *	2000-11-03	2000-12-20	Univ Manchester	Treatment of movement disorders
US7053092B2 (en)	2001-01-29	2006-05-30	Otsuka Pharmaceutical Co., Ltd.	5-HT1a receptor subtype agonist
WO2002102988A2 (en) *	2001-06-18	2002-12-27	Psychiatric Genomics, Inc.	Method for neural stem cell differentiation using 5ht-1a agonists
US20030036555A1 (en) *	2001-08-03	2003-02-20	Boehringer Ingelheim Pharma Kg	Pramipexole for the treatment of ADHD
AR033485A1 (es)	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
WO2005122767A1 (en) *	2004-06-10	2005-12-29	Mclean Hospital Corporation	Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
US7947661B2 (en) *	2004-08-11	2011-05-24	The Mclean Hospital Corporation	Compounds for the treatment of marihuana dependence, withdrawal, and usage
MY148644A (en)	2005-07-18	2013-05-15	Orion Corp	New pharmaceutical compounds
PE20070523A1 (es)	2005-09-12	2007-06-28	Wyeth Corp	Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
GT200600414A (es)	2005-09-12	2007-09-20		Sal de glucuranato de compuesto de piperazine
GT200600416A (es)	2005-09-12	2007-09-20		Sales salicilato y gentisato de un compuesto de piperazina
US9066903B2 (en) *	2006-02-28	2015-06-30	The United States Of America As Represented By The Department Of Veterans Affairs	Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) *	2006-06-23	2008-06-05	Spherics, Inc.	Dosage forms for movement disorder treatment
WO2008083442A1 (en) *	2007-01-10	2008-07-17	Brc Operations Pty Limited	Method for formulating combination medications for adhd
CN101318020B (zh) *	2007-06-06	2011-09-28	四川科瑞德制药有限公司	抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) *	2008-08-15	2010-02-18	Perry Renshaw	Methods and compositions for improving cognitive performance
GB201112987D0 (en)	2011-07-28	2011-09-14	Ge Healthcare Ltd	Novel compound
US10154988B2 (en)	2012-11-14	2018-12-18	The Johns Hopkins University	Methods and compositions for treating schizophrenia
US9463186B2 (en)	2013-04-15	2016-10-11	Northwestern University	Treatment for dopaminergic disorders
CN104892589A (zh)	2014-03-07	2015-09-09	中国科学院上海药物研究所	一类杂环化合物、其制备方法和用途
US11426366B2 (en)	2015-05-15	2022-08-30	Arizona Board Of Regents On Behalf Of The Universsity Of Arizona	Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990008148A1 (en) *	1989-01-23	1990-07-26	Pfizer Inc.	Bis-aza-bicyclic anxiolytic agents
WO1992000075A1 (en) *	1990-06-29	1992-01-09	Pfizer Inc.	Pyridopyrazine derivatives for treating substance abuse and addiction
US5281607B1 (en) *	1992-10-08	1998-05-19	Univ New York	Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) *	1994-04-23	1994-06-15	Boots Co Plc	Medical treatment
WO1995034555A1 (en) *	1994-06-14	1995-12-21	Pfizer Inc.	Benzimidazolone derivatives with central dopaminergic activity
US5877183A (en) *	1996-06-06	1999-03-02	Ergo Research Corporation	Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) *	1998-09-21	2000-11-11	Pfizer Prod Inc	Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

1999
- 1999-08-27 HN HN1999000146A patent/HN1999000146A/es unknown
- 1999-09-03 IL IL16483999A patent/IL164839A0/xx unknown
- 1999-09-03 YU YU21701A patent/YU21701A/sh unknown
- 1999-09-03 TR TR2004/02083T patent/TR200402083T2/xx unknown
- 1999-09-03 CA CA002344670A patent/CA2344670A1/en not_active Abandoned
- 1999-09-03 EP EP99939567A patent/EP1115402A1/en not_active Withdrawn
- 1999-09-03 OA OA1200100068A patent/OA11653A/en unknown
- 1999-09-03 TR TR2001/01357T patent/TR200101357T2/xx unknown
- 1999-09-03 AU AU53831/99A patent/AU760230B2/en not_active Ceased
- 1999-09-03 WO PCT/IB1999/001503 patent/WO2000016777A1/en not_active Ceased
- 1999-09-03 CZ CZ20011006A patent/CZ20011006A3/cs unknown
- 1999-09-03 JP JP2000573738A patent/JP2002526448A/ja active Pending
- 1999-09-03 ID IDW20010637A patent/ID28028A/id unknown
- 1999-09-03 EE EEP200100179A patent/EE200100179A/xx unknown
- 1999-09-03 GE GEAP19995812A patent/GEP20033081B/en unknown
- 1999-09-03 HR HR20010209A patent/HRP20010209A2/hr not_active Application Discontinuation
- 1999-09-03 EA EA200100204A patent/EA200100204A1/ru unknown
- 1999-09-03 KR KR10-2003-7014169A patent/KR20030088512A/ko not_active Ceased
- 1999-09-03 SK SK359-2001A patent/SK3592001A3/sk unknown
- 1999-09-03 IL IL14150799A patent/IL141507A0/xx unknown
- 1999-09-03 KR KR10-2004-7006381A patent/KR20040054752A/ko not_active Ceased
- 1999-09-03 NZ NZ509855A patent/NZ509855A/xx unknown
- 1999-09-03 CN CN99811132A patent/CN1319013A/zh active Pending
- 1999-09-03 EA EA200301063A patent/EA200301063A1/ru unknown
- 1999-09-03 HU HU0103691A patent/HUP0103691A3/hu unknown
- 1999-09-03 PL PL99346904A patent/PL346904A1/xx unknown
- 1999-09-03 KR KR10-2001-7003552A patent/KR100468340B1/ko not_active Expired - Fee Related
- 1999-09-03 BR BR9913975-8A patent/BR9913975A/pt not_active IP Right Cessation
- 1999-09-03 AP APAP/P/2001/002102A patent/AP1456A/en active
- 1999-09-13 GT GT199900154A patent/GT199900154A/es unknown
- 1999-09-15 TW TW088115941A patent/TW518225B/zh not_active IP Right Cessation
- 1999-09-15 PA PA19998482001A patent/PA8482001A1/es unknown
- 1999-09-17 PE PE1999000948A patent/PE20001084A1/es not_active Application Discontinuation
- 1999-09-17 AR ARP990104680A patent/AR029739A1/es unknown
- 1999-09-17 MY MYPI99004051A patent/MY127939A/en unknown
- 1999-09-20 TN TNTNSN99177A patent/TNSN99177A1/fr unknown
- 1999-09-20 MA MA25774A patent/MA26690A1/fr unknown
- 1999-09-20 DZ DZ990194A patent/DZ2894A1/xx active
- 1999-09-21 US US09/400,659 patent/US6300329B1/en not_active Expired - Fee Related
- 1999-09-21 CO CO99059863A patent/CO5140075A1/es unknown
2001
- 2001-02-20 IS IS5852A patent/IS5852A/is unknown
- 2001-03-20 NO NO20011409A patent/NO20011409L/no not_active Application Discontinuation
- 2001-04-13 BG BG105445A patent/BG105445A/xx unknown
- 2001-05-03 US US09/848,068 patent/US6608064B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
TR200101357T2 (tr)	2001-08-21
IL164839A0 (en)	2005-12-18
TNSN99177A1 (fr)	2005-11-10
HRP20010209A2 (en)	2002-04-30
KR20030088512A (ko)	2003-11-19
EA200100204A1 (ru)	2001-08-27
PL346904A1 (en)	2002-03-11
BR9913975A (pt)	2001-06-19
CN1319013A (zh)	2001-10-24
NO20011409D0 (no)	2001-03-20
US20010034347A1 (en)	2001-10-25
WO2000016777A1 (en)	2000-03-30
PA8482001A1 (es)	2000-05-24
KR100468340B1 (ko)	2005-01-27
BG105445A (en)	2001-12-29
EE200100179A (et)	2002-10-15
EP1115402A1 (en)	2001-07-18
HUP0103691A3 (en)	2003-01-28
ID28028A (id)	2001-05-03
US6300329B1 (en)	2001-10-09
IS5852A (is)	2001-02-20
YU21701A (sh)	2004-07-15
US6608064B2 (en)	2003-08-19
PE20001084A1 (es)	2000-10-18
TW518225B (en)	2003-01-21
AU5383199A (en)	2000-04-10
MA26690A1 (fr)	2004-12-20
KR20040054752A (ko)	2004-06-25
GEP20033081B (en)	2003-10-27
KR20010075222A (ko)	2001-08-09
AR029739A1 (es)	2003-07-16
HN1999000146A (es)	2000-11-11
DZ2894A1 (fr)	2003-12-15
CO5140075A1 (es)	2002-03-22
GT199900154A (es)	2001-03-06
SK3592001A3 (en)	2001-12-03
TR200402083T2 (tr)	2004-10-21
IL141507A0 (en)	2002-03-10
EA200301063A1 (ru)	2004-12-30
CZ20011006A3 (cs)	2001-09-12
JP2002526448A (ja)	2002-08-20
NZ509855A (en)	2003-04-29
CA2344670A1 (en)	2000-03-30
AU760230B2 (en)	2003-05-08
NO20011409L (no)	2001-03-28
HUP0103691A2 (hu)	2002-02-28
AP1456A (en)	2005-09-30
AP2001002102A0 (en)	2001-03-31
MY127939A (en)	2007-01-31

Publication	Publication Date	Title
US6608064B2 (en)	2003-08-19	Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microadenomas
US6232326B1 (en)	2001-05-15	Treatment for schizophrenia and other dopamine system dysfunctions
Baumann et al.	2000	Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications
JP2954029B2 (ja)	1999-09-27	神経活性物質の薬理学的スクリーニング法
CA2354237C (en)	2005-05-24	A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (adhd)
CN101400348A (zh)	2009-04-01	用于提高记忆功能的四氢异喹啉衍生物
CA3149989A1 (en)	2021-03-11	Methods of treating epilepsy using the same
Ozaki et al.	1959	Monoamine oxidase inhibitors and procedures for their evaluation in vivo and in vitro
US20050054734A1 (en)	2005-03-10	Therapeutic treatment for the metabolic syndrome, type2 diabetes, obesity, or prediabetes
US20050054652A1 (en)	2005-03-10	Methods of treating metabolic syndrome using dopamine receptor agonists
WO2002058687A2 (en)	2002-08-01	Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics
Baumeister et al.	2004	The serotonin hypothesis of schizophrenia: a historical case study on the heuristic value of theory in clinical neuroscience
JPWO2009069828A1 (ja)	2011-04-21	パーキンソン病の運動合併症または精神症状を改善する薬剤
US20040220190A1 (en)	2004-11-04	Methods of treating metabolic syndrome using dopamine receptor agonists
Leonard	1985	Current status of the biogenic amine theory of depression
Obradovic et al.	1996	Methylenedioxymethamphetamine-induced inhibition of neuronal firing in the nucleus accumbens is mediated by both serotonin and dopamine
AU689783B2 (en)	1998-04-09	Utilization of efaroxan and derivatives thereof for the preparation of a medicament intended to the treatment of Parkinson disease
RU2508106C2 (ru)	2014-02-27	Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
MXPA01002946A (en)	2001-12-04	Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
HK1039574A1 (zh)	2002-05-03	治疗帕金森氏病、adhd和微腺瘤的药物试剂
RU2508096C2 (ru)	2014-02-27	Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
MXPA01007762A (en)	2002-06-05	A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (adhd) comprising a nicotine receptor partial agonist and anti-adhd agent
RU2494738C2 (ru)	2013-10-10	Применение ингибиторов пкс при трансплантации
WO2025186320A1 (en)	2025-09-12	Combinations of beta 2-adrenergic receptor agonists and sglt2 inhibitors for use in treating hyperglycaemia or a disorder characterized by hyperglycaemia
Verstraete	1984	Drugs acting on the peripheral circulation